Well done to all the RVA shareholders the last month has been a great result. I see many similiarities between RVA & UBI both have borrowed funds in their balance sheet, fortunately RVA technolgy has been recognised by the market, while after many months of waiting UBI second product has now received the tick of approval into European markets, so suspect it could now follow a similiar path to RVA. Whilst rhese companies can at times lack liquidity there are superior to cheap mining companies in that they are dealing with technolgy & not a finite resource. These companies are also far better than companies that have to await drug approval but their pathway to revenue is far shorter, just look at NAN as a guide.
Regards
Buffett
RVA Price at posting:
46.5¢ Sentiment: None Disclosure: Not Held
